Evidence map›Paper›PMID 35344520›Full record

Trial reportJournal of acquired immune deficiency syndromes (1999)2022

Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.

Erica N Browne, Elizabeth R Brown, Thesla Palanee-Phillips, Krishnaveni Reddy, Logashvari Naidoo, Nitesha Jeenarain, Gonasagrie Nair, Marla J Husnik, Devika Singh, Rachel Scheckter and 4 more

Abstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Journal of acquired immune deficiency syndromes (1999), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Erica N BrowneWomen's Global Health Imperative, RTI International, Berkeley, CA.ORCID 0000-0003-2069-6589
Elizabeth R BrownFred Hutchinson Cancer Research Center, Seattle, WA.
Thesla Palanee-PhillipsWits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Faculty of Health, Sciences, Johannesburg, South Africa.
Krishnaveni ReddyWits Reproductive Health and HIV Institute (Wits RHI), University of the Witwatersrand, Faculty of Health, Sciences, Johannesburg, South Africa.
Logashvari NaidooSouth African Medical Research Council, HPRU, Durban, South Africa.
Nitesha JeenarainSouth African Medical Research Council, HPRU, Durban, South Africa.
Gonasagrie NairCAPRISA, Durban, South Africa.
Marla J HusnikFred Hutchinson Cancer Research Center, Seattle, WA.
Devika SinghUniversity of Pittsburgh, and Magee-Women's Research Institute, Pittsburgh, PA.
Rachel ScheckterFHI 360, Durham, NC.
Lydia Soto-TorresDivision of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.
Jared M BaetenDepartment of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, WA.
Ariane van der StratenCenter for AIDS Prevention Studies, Department of Medicine, University of California, San Francisco, CA.
MTN-020/ASPIRE Study Team

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Microbicide Trials NetworkU01AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2006 to 2010
$77.0M
Statistical and Data Management Center (SDMC): Microbicide Trials NetworkUM1AI068615 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BROWN, ELIZABETH RENATA · 2011 to 2021
$66.5M
WG3: HIV, Co-infections and Co-morbiditiesP30AI036219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI Immaculate Lillian Nankya · 1994 to 2026
$50.0M
University of KwaZulu-Natal - CAPRISA HIV/AIDS Clinical Trials UnitUM1AI069469 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI QUARRAISHA ABDOOL KARIM · 2012 to 2026
$36.4M
Wits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationUM1AI069463 · NIAID · WITS HEALTH CONSORTIUM (PTY), LTD · PI REES, HELEN, SANNE, IAN MATTHIAS · 2012 to 2025
$31.8M
Laboratory Center (LC): Microbicide Trials NetworkUM1AI106707 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI MELLORS, JOHN W, ROHAN, LISA CENCIA · 2014 to 2021
$27.1M
NIAID NIH HHS P30 AI036219NIAID NIH HHS U01 AI068633NIAID NIH HHS UM1 AI068615NIAID NIH HHS UM1 AI068633NIAID NIH HHS UM1 AI069463NIAID NIH HHS UM1 AI069469NIAID NIH HHS UM1 AI106707
6 · The paper itself

Abstract

backgroundPersistent use of HIV prevention methods can be a challenge, particularly for some younger women. The long-acting, discreet, woman-centric dapivirine vaginal ring offers promise as a prevention method with less user burden, which could support continued use. We assessed dapivirine vaginal ring use to understand adherence patterns and identify characteristics influencing patterns.

settingParticipants enrolled in South Africa in the MTN-020/ASPIRE randomized placebo-controlled trial.

methodsWe used group-based trajectory modeling to identify clusters of participants with similar longitudinal patterns of adherence in the last year of participation and potential predictors of group membership. Women with at least 1 year of follow-up were included (n = 626).

resultsFive adherence patterns were identified: (1) consistently high, 34%, (2) consistently moderate, 34%, (3) consistently low, 16%, (4) decreasing, 9%, and (5) increasing, 7%. Women younger than 22 years [adjusted odds ratio (AOR) 1.8, 95% confidence interval (CI): 1.0 to 3.0], using an intrauterine device (AOR 3.3, 95% CI: 1.4 to 7.8) or oral contraceptives (AOR 3.9, 95% CI: 1.7 to 8.9), experiencing menses (AOR 1.8, 95% CI: 1.1 to 3.0), and who reported inconsistent condom use (AOR 1.8, 95% CI: 1.0 to 3.3) were more likely to be classified as consistently low compared to consistently high (referent).

conclusionsMost South African women successfully persisted with a moderate or high level of use. Encouraging ring replacement with completion of menses may help to decrease concerns about hygiene and improve persistence. Associations between contraception and persistent low adherence suggest efforts may be needed to ensure contraceptive method choice does not interfere with ring use.

Indexed as

Anti-HIV AgentsContraceptive Devices, FemaleHIV-1HIV InfectionsFemaleHumansPyrimidinesSouth AfricaAnti-HIV AgentsDapivirinePyrimidines

Identifiers

PMID35344520
PMCPMC9342948

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.